Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 2,540 shares of the stock in a transaction on Monday, August 28th. The stock was sold at an average price of $197.39, for a total value of $501,370.60. Following the transaction, the director now owns 539,176 shares of the company’s stock, valued at $106,427,950.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of Illumina, Inc. (NASDAQ ILMN) traded up 1.94% during trading on Wednesday, reaching $199.74. The company’s stock had a trading volume of 798,799 shares. The company’s 50 day moving average price is $183.92 and its 200 day moving average price is $176.00. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $200.00. The firm has a market cap of $29.16 billion, a PE ratio of 40.08 and a beta of 0.83.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm had revenue of $662 million during the quarter, compared to analyst estimates of $642.38 million. During the same quarter in the prior year, the company earned $0.86 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. On average, equities analysts predict that Illumina, Inc. will post $3.65 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Illumina, Inc. (ILMN) Director Jay T. Flatley Sells 2,540 Shares” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.watchlistnews.com/illumina-inc-ilmn-director-jay-t-flatley-sells-2540-shares/1532598.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Illumina by 2.6% in the second quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock valued at $1,718,601,000 after buying an additional 255,498 shares in the last quarter. Capital World Investors raised its position in shares of Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after buying an additional 410,000 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after buying an additional 527,548 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Illumina by 8.0% in the first quarter. Geode Capital Management LLC now owns 1,458,071 shares of the life sciences company’s stock valued at $248,460,000 after buying an additional 107,941 shares in the last quarter. Finally, Winslow Capital Management LLC purchased a new position in shares of Illumina during the second quarter valued at about $211,584,000. 93.32% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have issued reports on the company. BidaskClub lowered Illumina from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Barclays PLC reiterated an “equal weight” rating and set a $150.00 price objective on shares of Illumina in a research note on Wednesday, August 9th. Vetr upgraded Illumina from a “hold” rating to a “buy” rating and set a $209.78 price objective for the company in a research note on Wednesday, August 9th. Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and increased their price objective for the stock from $170.00 to $215.00 in a research note on Monday, August 7th. Finally, Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $177.01.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.